Literature DB >> 10679918

t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia.

M Bentz1, A Plesch, L Bullinger, S Stilgenbauer, G Ott, H K Müller-Hermelink, M Baudis, T F Barth, P Möller, P Lichter, H Döhner.   

Abstract

Until now, few data on additional chromosomal aberrations in t(11;14)-positive mantle cell lymphomas (MCLs) have been published. We analyzed 39 t(11;14)-positive MCLs by either comparative genomic hybridization (CGH; n = 8), fluorescence in situ hybridization (FISH) with a set of DNA probes detecting the most frequent aberrations in B-cell neoplasms (n = 12), or both techniques (n = 19). The t(11;14) was present in all cases. In 37 of 39 cases, chromosomal imbalances were found. In 27 cases, complex karyotypes, i.e., >/= 3 aberrations, were identified. The most frequent aberrations were losses of 13q14-21 or 13q32-34 (27 cases), 9p21 (16 cases), and 11q22-23 (12 cases) and gains of 3q26-29 (19 cases), 8q22-24 (11 cases), and 18q21-22 (9 cases). In 26% of cases (7 of 27) analyzed by CGH, a total of 10 high-level DNA amplifications were identified. Although in comparison with B-cell chronic lymphopcytic leukemia (B-CLL) MCL is characterized by a much higher complexity of chromosomal aberrations, there are striking similarities: 13q14 deletions were identified in more than 50% of both MCL and B-CLL cases. In contrast, in our CGH database containing 293 B-cell lymphomas, this aberration was found in only 11% of other nodal lymphomas. Even more strikingly, 11q deletions, which are present in 20%-30 % of MCL and B-CLL, were found very rarely in other nodal B-cell lymphomas (CGH: 1 of 208 cases; FISH: 1 of 69 cases). These data show that MCL is characterized by specific secondary aberrations and that there may be similarities in the pathogenesis of MCL and B-CLL. Genes Chromosomes Cancer 27:285-294, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10679918

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 2.  Management of Older Adults with Mantle Cell Lymphoma.

Authors:  Jason T Romancik; Jonathon B Cohen
Journal:  Drugs Aging       Date:  2020-07       Impact factor: 3.923

Review 3.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

4.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Authors:  Matthew S Davids; Andrew W Roberts; John F Seymour; John M Pagel; Brad S Kahl; William G Wierda; Soham Puvvada; Thomas J Kipps; Mary Ann Anderson; Ahmed Hamed Salem; Martin Dunbar; Ming Zhu; Franklin Peale; Jeremy A Ross; Lori Gressick; Monali Desai; Su Young Kim; Maria Verdugo; Rod A Humerickhouse; Gary B Gordon; John F Gerecitano
Journal:  J Clin Oncol       Date:  2017-01-17       Impact factor: 44.544

Review 5.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

6.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.

Authors:  Elena M Hartmann; Elias Campo; George Wright; Georg Lenz; Itziar Salaverria; Pedro Jares; Wenming Xiao; Rita M Braziel; Lisa M Rimsza; Wing-Chung Chan; Dennis D Weisenburger; Jan Delabie; Elaine S Jaffe; Randy D Gascoyne; Sandeep S Dave; Hans-Konrad Mueller-Hermelink; Louis M Staudt; German Ott; Sílvia Beà; Andreas Rosenwald
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

Review 7.  Pitfalls of Combining Novel Agents in Lymphoma.

Authors:  Thomas D Rodgers; Paul M Barr
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

9.  The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.

Authors:  Shuhua Yi; Heng Li; Zengjun Li; Wenjie Xiong; Huimin Liu; Wei Liu; Rui Lv; Zhen Yu; Dehui Zou; Yan Xu; Gang An; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-24       Impact factor: 2.490

10.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Authors:  Sílvia Beà; Itziar Salaverria; Lluís Armengol; Magda Pinyol; Verónica Fernández; Elena M Hartmann; Pedro Jares; Virginia Amador; Luís Hernández; Alba Navarro; German Ott; Andreas Rosenwald; Xavier Estivill; Elias Campo
Journal:  Blood       Date:  2008-11-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.